{
  "story_id": "b95b5026bbd6194d3fb2197a06fed7d7",
  "desk": "drm3",
  "revision": 1,
  "published_at": "2026-11-18T22:00:07.000Z",
  "content_hash": "ddaa83f9e62c433d64fa233022ce9ed28e4ddae573b3d8cf91a873f4c8f91d79",
  "hash_basis": "sha256 over `headline\\ndek\\nprose`, plus `\\n` + the canonical citations JSON when any source is placed, plus `\\n#blog` for blogs",
  "basis": {
    "headline": "FDA Approves New Treatment for Rare Genetic Disorder Niemann-Pick Disease Type C",
    "dek": "FDA approves adrabetadex for infantile-onset Niemann-Pick disease type C, showing 55% reduced risk of death.",
    "prose": "The approval was supported by survival data from 36 patients across three clinical studies and an expanded access program, where treatment with adrabetadex was associated with a 55% reduction in the risk of death compared with matched external controls. [^1]\n\nThe FDA approved adrabetadex (Lembaz) injection on Tuesday for patients with infantile-onset Niemann-Pick disease type C (NPC), a rare and fatal genetic disorder. [^2][^3] The approval marks the culmination of 20 years of foundational scientific research. [^4] The drug addresses the issues caused by NPC, which is a rare and rapidly fatal pediatric neurodegenerative disorder. [^5]\n\nThe drug, developed by researchers at the National Institutes of Health (NIH) and Beren Therapeutics, extended the survival of participants in a large international clinical trial. [^6] Adrabetadex is indicated for adults and children weighing at least 15 lb whose neurological symptoms began before age 6 years, targeting the cholesterol that accumulates inside brain cells and drives progressive neurological damage. [^7] Median overall survival was 8.5 years among patients treated with adrabetadex compared with 4.9 years in the control group. [^8]",
    "cited": "[{\"statement\":\"The approval was supported by survival data from 36 patients across three clinical studies and an expanded access program, where treatment with adrabetadex was associated with a 55% reduction in the risk of death compared with matched external controls.\",\"source\":\"MedpageToday\",\"instrument\":\"News\",\"claim_key\":null,\"url\":\"https://www.medpagetoday.com/genetics/generalgenetics/123945\"},{\"statement\":\"The FDA approved adrabetadex (Lembaz) injection on Tuesday for patients with infantile-onset Niemann-Pick disease type C (NPC), a rare and fatal genetic disorder.\",\"source\":\"MedpageToday\",\"instrument\":\"News\",\"claim_key\":null,\"url\":\"https://www.medpagetoday.com/genetics/generalgenetics/123945\"},{\"statement\":\"The U.S. Food and Drug Administration (FDA) approved cyclodextrin (brand name Adrabetadex) for the treatment of infants with Niemann-Pick type C (NPC) disease.\",\"source\":\"Medical Xpress\",\"instrument\":\"News\",\"claim_key\":null,\"url\":\"https://medicalxpress.com/news/2026-11-fda-drug-infantile-onset-niemann.html\"},{\"statement\":\"The approval marks the culmination of 20 years of foundational scientific research.\",\"source\":\"Medical Xpress\",\"instrument\":\"News\",\"claim_key\":null,\"url\":\"https://medicalxpress.com/news/2026-11-fda-drug-infantile-onset-niemann.html\"},{\"statement\":\"The drug addresses the issues caused by NPC, which is a rare and rapidly fatal pediatric neurodegenerative disorder.\",\"source\":\"Medical Xpress\",\"instrument\":\"News\",\"claim_key\":null,\"url\":\"https://medicalxpress.com/news/2026-11-fda-drug-infantile-onset-niemann.html\"},{\"statement\":\"The drug, developed by researchers at the National Institutes of Health (NIH) and Beren Therapeutics, extended the survival of participants in a large international clinical trial.\",\"source\":\"Medical Xpress\",\"instrument\":\"News\",\"claim_key\":null,\"url\":\"https://medicalxpress.com/news/2026-11-fda-drug-infantile-onset-niemann.html\"},{\"statement\":\"Adrabetadex is indicated for adults and children weighing at least 15 lb whose neurological symptoms began before age 6 years, targeting the cholesterol that accumulates inside brain cells and drives progressive neurological damage.\",\"source\":\"MedpageToday\",\"instrument\":\"News\",\"claim_key\":null,\"url\":\"https://www.medpagetoday.com/genetics/generalgenetics/123945\"},{\"statement\":\"Median overall survival was 8.5 years among patients treated with adrabetadex compared with 4.9 years in the control group.\",\"source\":\"MedpageToday\",\"instrument\":\"News\",\"claim_key\":null,\"url\":\"https://www.medpagetoday.com/genetics/generalgenetics/123945\"}]",
    "kind": "news"
  },
  "receipt_verify": "Ed25519 over the dot-joined string `slice_hash.cursor_from.cursor_to.view.view_version.row_count`; public_key and sig are base64url of the raw 32-byte key / 64-byte signature",
  "receipt": {
    "slice_hash": "e121faf346f473c96289c14ab998db21d00643e0309667301a1f6484a4efff1d",
    "cursor_from": "ingest:raw_newsroomfloor.stories:e121faf346f473c9",
    "cursor_to": "ingest:raw_newsroomfloor.stories:e121faf346f473c9",
    "view": "ingest:raw_newsroomfloor.stories",
    "view_version": "1",
    "row_count": 1,
    "hash_basis": "sha256 over the JSON array of {insertId, json} rows as received (normalized wire shape), computed before the BigQuery forward",
    "credits": 0.01,
    "price_per_100_rows_written": 1,
    "sig": "GqKKR7_gO_dGYAAG6hxy86eyqz3X4_dZXdZI_EnDU-Vi1wEq3nFbF9aaFDt58FhN_cQc9LrcMsEUNp7T3ONGDA",
    "public_key": "bMUigy8O0jOnBxQ4Sc-5lwhIZ8LQVAhxMbR7qESVuUE",
    "signer_path": "lakehouse/data-extract/v1",
    "alg": "Ed25519",
    "signed": true
  },
  "receipt_note": "the ingest door's signed receipt for this revision, verbatim as the door returned it",
  "generation_chain": {
    "wire": {
      "stream": "fountain_news",
      "story_id": "1b7105d29b8d2440be4f6bcb172db7a0",
      "thread_id": "baf67b46735ee83b462f022002a11189",
      "thread_label": "Beren Therapeutics",
      "novelty": "UPDATE",
      "content_hash": "2319af9f4645f9d043f096f9b0023b7df102144d5eb50643742f675c19be3d0a",
      "compose": 3,
      "last_published_at": "2026-11-18T22:00:07.000Z",
      "read_receipt": {
        "slice_hash": "88a60e88b4b433a6abd1b39be604d9f09db6fe2a864e1b5c63ef5c859e7bf28a",
        "cursor_from": "eyJ0cyI6IjIwMjYtMTEtMThUMjE6NTM6MzguMDAwWiIsImlkIjoiMTM1ZTUyZmUzNDhmNWQ3OWQ3NzI0NTIzMjE2YWUyYmIiLCJ2IjoiMSJ9",
        "cursor_to": "eyJ0cyI6IjIwMjYtMTEtMTlUMDM6NTE6NTguMDAwMDAwWiIsImlkIjoiN2UxZjk0MzRhNjJkY2MxZDNmOTcwNzQ1ODEyZTE0ZDIiLCJ2IjoiMSJ9",
        "view": "v_fountain_news",
        "view_version": "1",
        "row_count": 100,
        "window_days": 3,
        "bytes_scanned": 3577351,
        "credits": 8,
        "price_per_100_rows": 8,
        "sig": "VtX4HDc32Ha7kHpdOhOLilS3ywINUJs0G4fsvJoJTcItQQM8R52uyHBGpftLRSJGi-XmaV_2pIUBGJYQRj3CDw",
        "public_key": "bMUigy8O0jOnBxQ4Sc-5lwhIZ8LQVAhxMbR7qESVuUE",
        "signer_path": "lakehouse/data-extract/v1",
        "alg": "Ed25519",
        "signed": true
      },
      "landing": "air"
    },
    "written_at": "2026-11-19T21:57:00.740Z"
  },
  "cited_facts": [
    {
      "n": 1,
      "statement": "The approval was supported by survival data from 36 patients across three clinical studies and an expanded access program, where treatment with adrabetadex was associated with a 55% reduction in the risk of death compared with matched external controls.",
      "source": "MedpageToday",
      "instrument": "News",
      "claim_key": null,
      "url": "https://www.medpagetoday.com/genetics/generalgenetics/123945",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 2,
      "statement": "The FDA approved adrabetadex (Lembaz) injection on Tuesday for patients with infantile-onset Niemann-Pick disease type C (NPC), a rare and fatal genetic disorder.",
      "source": "MedpageToday",
      "instrument": "News",
      "claim_key": null,
      "url": "https://www.medpagetoday.com/genetics/generalgenetics/123945",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 3,
      "statement": "The U.S. Food and Drug Administration (FDA) approved cyclodextrin (brand name Adrabetadex) for the treatment of infants with Niemann-Pick type C (NPC) disease.",
      "source": "Medical Xpress",
      "instrument": "News",
      "claim_key": null,
      "url": "https://medicalxpress.com/news/2026-11-fda-drug-infantile-onset-niemann.html",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 4,
      "statement": "The approval marks the culmination of 20 years of foundational scientific research.",
      "source": "Medical Xpress",
      "instrument": "News",
      "claim_key": null,
      "url": "https://medicalxpress.com/news/2026-11-fda-drug-infantile-onset-niemann.html",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 5,
      "statement": "The drug addresses the issues caused by NPC, which is a rare and rapidly fatal pediatric neurodegenerative disorder.",
      "source": "Medical Xpress",
      "instrument": "News",
      "claim_key": null,
      "url": "https://medicalxpress.com/news/2026-11-fda-drug-infantile-onset-niemann.html",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 6,
      "statement": "The drug, developed by researchers at the National Institutes of Health (NIH) and Beren Therapeutics, extended the survival of participants in a large international clinical trial.",
      "source": "Medical Xpress",
      "instrument": "News",
      "claim_key": null,
      "url": "https://medicalxpress.com/news/2026-11-fda-drug-infantile-onset-niemann.html",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 7,
      "statement": "Adrabetadex is indicated for adults and children weighing at least 15 lb whose neurological symptoms began before age 6 years, targeting the cholesterol that accumulates inside brain cells and drives progressive neurological damage.",
      "source": "MedpageToday",
      "instrument": "News",
      "claim_key": null,
      "url": "https://www.medpagetoday.com/genetics/generalgenetics/123945",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 8,
      "statement": "Median overall survival was 8.5 years among patients treated with adrabetadex compared with 4.9 years in the control group.",
      "source": "MedpageToday",
      "instrument": "News",
      "claim_key": null,
      "url": "https://www.medpagetoday.com/genetics/generalgenetics/123945",
      "occurred_at": null,
      "published_at": null
    }
  ],
  "note": "A signature proves who filed this and that it has not changed since. It never makes a claim true. The dates on cited_facts (occurred_at, published_at) are the forge's, joined at read time; they are not part of the signed basis above."
}